[go: up one dir, main page]

ES2529261T3 - Polipéptidos estabilizados del factor de crecimiento similares a insulina - Google Patents

Polipéptidos estabilizados del factor de crecimiento similares a insulina Download PDF

Info

Publication number
ES2529261T3
ES2529261T3 ES07798148.8T ES07798148T ES2529261T3 ES 2529261 T3 ES2529261 T3 ES 2529261T3 ES 07798148 T ES07798148 T ES 07798148T ES 2529261 T3 ES2529261 T3 ES 2529261T3
Authority
ES
Spain
Prior art keywords
insulin
growth factor
precursor protein
stabilized polypeptides
factor stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07798148.8T
Other languages
English (en)
Inventor
David Jonathan Glass
Mara Fornaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2529261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2529261T3 publication Critical patent/ES2529261T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

Una proteína precursora del IGF-1 humano, en donde: (i) uno o más de los siguientes residuos de la proteína precursora se suprimen o mutan: G1, P2, E3, R36 y R37; y (ii) la escisión del péptido E de IGF-1 mediante una proteasa se reduce mediante la modificación de la proteína precursora, en donde la modificación es la supresión o mutación de R71 o S72 de la proteína precursora.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25

Claims (1)

  1. imagen1
    imagen2
ES07798148.8T 2006-06-09 2007-06-06 Polipéptidos estabilizados del factor de crecimiento similares a insulina Active ES2529261T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US812349P 2006-06-09
US86224406P 2006-10-20 2006-10-20
US862244P 2006-10-20
US89718707P 2007-01-24 2007-01-24
US897187P 2007-01-24
PCT/US2007/070468 WO2007146689A2 (en) 2006-06-09 2007-06-06 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
ES2529261T3 true ES2529261T3 (es) 2015-02-18

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07798148.8T Active ES2529261T3 (es) 2006-06-09 2007-06-06 Polipéptidos estabilizados del factor de crecimiento similares a insulina

Country Status (32)

Country Link
US (4) US20100173839A1 (es)
EP (2) EP2032155B1 (es)
JP (2) JP2009539805A (es)
KR (1) KR101459789B1 (es)
AR (1) AR061242A1 (es)
AU (2) AU2007257936B2 (es)
BR (2) BRPI0712147A2 (es)
CA (2) CA2654944C (es)
CL (1) CL2007001614A1 (es)
CR (2) CR10432A (es)
CY (1) CY1116117T1 (es)
DK (2) DK2032155T3 (es)
EC (1) ECSP088949A (es)
ES (1) ES2529261T3 (es)
GT (1) GT200800273A (es)
HR (1) HRP20150326T1 (es)
IL (1) IL195156A (es)
JO (1) JO2968B1 (es)
MA (1) MA30503B1 (es)
MX (2) MX2008015726A (es)
MY (1) MY147856A (es)
NO (2) NO20085183L (es)
NZ (2) NZ572708A (es)
PE (1) PE20080715A1 (es)
PL (1) PL2032155T3 (es)
PT (1) PT2032155E (es)
RU (1) RU2477287C2 (es)
SI (1) SI2032155T1 (es)
TN (1) TNSN08509A1 (es)
TW (1) TWI427084B (es)
UA (1) UA97953C2 (es)
WO (2) WO2007146689A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
MX2008015726A (es) 2006-06-09 2008-12-19 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada.
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
EP2356148A2 (en) * 2008-11-10 2011-08-17 Novartis AG Antibodies to modified human igf-1/e peptides
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
HUE035240T2 (hu) 2009-04-27 2018-05-02 Novartis Ag Készítmények és eljárások az izomerõ növelésére
KR101417872B1 (ko) * 2009-07-22 2014-07-09 입센 파마 에스.에이.에스 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(ｉｇｆ-1)의 유사체
EP2498796B1 (en) 2009-11-09 2017-12-27 AAL Scientifics, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
CN108752461A (zh) 2011-02-23 2018-11-06 麻省理工学院 水溶性膜蛋白及其制备和使用方法
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
WO2013006437A1 (en) 2011-07-01 2013-01-10 Novartis Ag Method for treating metabolic disorders
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
MA38153B1 (fr) * 2012-12-18 2018-06-29 Novartis Ag Polypeptides stabilisés de facteur de croissance de type insuline
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
US20160200818A1 (en) 2013-08-14 2016-07-14 Novartis Ag Methods of treating Sporadic Inclusion Body Myositis
EP3052123A1 (en) 2013-10-02 2016-08-10 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
MX371329B (es) 2013-12-19 2020-01-27 Puretein Bioscience Llc Factor de creciemiento similar a la insulina (igf) activo y su uso en infecciones por el virus del síndrome reproductivo y respiratorio porcino (prrsv).
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2016126924A1 (en) * 2015-02-04 2016-08-11 Puretein Bioscience Llc Methods for increasing performance characteristics in offspring
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
EP3600415B1 (en) 2017-03-24 2025-09-17 Novartis AG Antibody against activin receptor type ii receptor for use in treating heart failure
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) * 2022-01-31 2023-11-01 國立大學法人信州大學 以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞
CN119569848A (zh) * 2024-11-22 2025-03-07 福建省农业科学院畜牧兽医研究所 一种鸭源igf2重组蛋白及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987001038A1 (en) 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
EP0346429B1 (en) 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
AU1178395A (en) 1993-11-12 1995-05-29 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
CA2190752A1 (en) 1994-05-24 1995-11-30 George N. Cox Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) * 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
WO2000040613A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
US7083970B2 (en) * 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CA2594023C (en) * 2005-01-07 2015-07-14 Regeneron Pharmaceuticals, Inc. Igf-i fusion polypeptides and therapeutic uses thereof
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
WO2006097764A1 (en) 2005-03-18 2006-09-21 Ucl Business Plc Mecano growth factor peptides and their use
JP4713579B2 (ja) 2005-03-31 2011-06-29 パイオニア株式会社 アプリケーションプログラム
MX2008015726A (es) 2006-06-09 2008-12-19 Novartis Ag Polipeptidos de factor de crecimiento de tipo insulina estabilizada.

Also Published As

Publication number Publication date
MY147856A (en) 2013-01-31
TNSN08509A1 (en) 2010-04-14
CA2653781A1 (en) 2007-12-13
TWI427084B (zh) 2014-02-21
BRPI0712147A2 (pt) 2012-02-22
US20130059779A1 (en) 2013-03-07
UA97953C2 (uk) 2012-04-10
DK2032155T3 (en) 2015-03-02
CL2007001614A1 (es) 2008-08-08
CR20160115A (es) 2016-06-14
RU2008151511A (ru) 2010-07-20
AU2007257936A1 (en) 2007-12-21
CR10432A (es) 2009-01-15
NO20085184L (no) 2009-03-03
KR101459789B1 (ko) 2014-11-07
HRP20150326T1 (hr) 2015-04-24
NO20085183L (no) 2009-03-09
PL2032155T3 (pl) 2015-05-29
JP5290966B2 (ja) 2013-09-18
SI2032155T1 (sl) 2015-04-30
ECSP088949A (es) 2009-01-30
JP2009539805A (ja) 2009-11-19
US20140235538A1 (en) 2014-08-21
RU2477287C2 (ru) 2013-03-10
MX2008015657A (es) 2009-02-04
US20170066808A9 (en) 2017-03-09
WO2007146689A3 (en) 2008-04-10
CA2654944A1 (en) 2007-12-21
WO2007146689A2 (en) 2007-12-21
CA2654944C (en) 2017-01-03
EP2032154A2 (en) 2009-03-11
JO2968B1 (en) 2016-03-15
US8722621B2 (en) 2014-05-13
WO2007141309A2 (en) 2007-12-13
IL195156A (en) 2014-07-31
PT2032155E (pt) 2015-04-07
AU2007257936B2 (en) 2011-05-26
IL195156A0 (en) 2011-08-01
CY1116117T1 (el) 2017-02-08
KR20090027197A (ko) 2009-03-16
WO2007141309A3 (en) 2008-05-29
TW200835698A (en) 2008-09-01
HK1126429A1 (en) 2009-09-04
GT200800273A (es) 2009-09-16
EP2032155A2 (en) 2009-03-11
EP2032155B1 (en) 2014-12-24
US20100234290A1 (en) 2010-09-16
BRPI0712052A2 (pt) 2012-01-10
MA30503B1 (fr) 2009-06-01
JP2009539383A (ja) 2009-11-19
US20100173839A1 (en) 2010-07-08
DK200900016A (da) 2009-01-06
US8343918B2 (en) 2013-01-01
AU2007255419A1 (en) 2007-12-13
NZ572548A (en) 2011-06-30
PE20080715A1 (es) 2008-07-25
MX2008015726A (es) 2008-12-19
AR061242A1 (es) 2008-08-13
WO2007146689A9 (en) 2010-12-16
NZ572708A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
ES2529261T3 (es) Polipéptidos estabilizados del factor de crecimiento similares a insulina
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
WO2008066583A3 (en) Cell-free synthesis of proteins containing unnatural amino acids
ES2677246T3 (es) Anticuerpo que se dirige a la proteína Siglec-15 relacionada con osteoclastos
EP4365189A3 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
IL217488A (en) Mt – sp1 polypeptides with specific or variable activity to the substrate with preparations and uses based on these polypeptides
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
CY1109779T1 (el) Αναστολεις της hcv ns-3 πρωτεασης σερινης
MX2022004316A (es) Composiciones y metodos para sintesis in vivo de polipeptidos no naturales.
WO2004009819A3 (en) Polypeptides with a signal sequence comprising an fivsi motif and olynucleotides encoding therefor
EP2290087A3 (en) Methods for producing soluble multi-membrane-spanning proteins
WO2004074315A3 (en) Analogues of glp-1
ATE455125T1 (de) Tool für den transfer und die herstelung von proteinen mit dem pseudomonas-typ-iii- sekretionssystem
UY27439A1 (es) Procedimiento para sintetizar un conjunto de oligomero-polipeptido insulina, conjugado oligomero-polipeptido de proinsulina, composicion de conjugado oligomero-insulina, procedimiento para sintetizar un conjugado oligomero-polipeptido c-peptido, conj
EP2014676A4 (en) MUTANT OF THE HGF PRECURSOR PROTEIN AND ACTIVATED FORM THEREOF
CO2025002728A2 (es) Proteínas de fusión de il-18 y métodos para producir il-18
CR20240372A (es) Péptidos agonistas duales de glp-1 y glucagón con estabilidad biológica mejorada
CO2025016437A2 (es) Métodos de uso de proteínas de fusión il-18
Aggarwal et al. Modifications in the Kex2 P1’cleavage site in the α-MAT secretion signal lead to higher production of human granulocyte colony-stimulating factor in Pichia pastoris
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
EP2210900A3 (en) Analogues of GLP-1
WO2007016482A3 (en) Mutant timp-3
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
WO2007005738A3 (en) Glp-1 pharmaceutical compositions
WO2023220658A3 (en) Recombinant neprosin polypeptides and methods of expression